Analytical Data
-
Gene name
ITGaE
- Application
-
Alternative Names
CD103; ITG-AE; ITGA-E; Mucosal Lymphocyte Antigen 1; HML-1 antigen; Integrin alpha-IEL
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q60677
-
Expression Region
Val671~Gln917
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ITGaE, or integrin alpha E, is a crucial protein that plays a significant role in various biological processes, including cell adhesion, immune response, and tissue development. Research into ITGaE has gained momentum due to its involvement in several pathological conditions, such as cancer metastasis, autoimmune diseases, and infectious diseases, making it a potential target for therapeutic intervention. The integrin family of proteins, including ITGaE, functions as receptors that mediate the interaction between cells and the extracellular matrix (ECM), influencing cellular behavior and gene expression. The heterodimeric nature of integrins, where ITGaE pairs with its beta counterpart, further complicates their functional dynamics, necessitating in-depth studies of their structure and interactions. Advances in recombinant protein technology have enabled researchers to produce ITGaE in manageable quantities, facilitating investigations into its molecular structure and functional roles. By understanding the mechanisms through which ITGaE operates, scientists aim to uncover its contributions to cell signaling pathways and potential implications in therapeutic development. The reconstitution of ITGaE and its binding partners in vitro is crucial for delineating its specific functions under various physiological and pathological conditions. As ongoing research sheds light on the complexities of integrin biology, ITGaE continues to emerge as a key player in therapeutic strategies aimed at manipulating immune responses and targeting cancer progression. This evolving interest highlights the significance of ITGaE in biomedical research and its potential to influence future clinical applications.
